首页 > 最新文献

International journal of drug discovery and pharmacology最新文献

英文 中文
Oxidized LDL Regulates Endothelin-1 and Oxidative Stress in Vascular Endothelial Cells: Role of Extracellular Regulated Kinase1/2 (ERK1/2) 氧化LDL调节血管内皮细胞内皮素-1和氧化应激:细胞外调节激酶1/2 (ERK1/2)的作用
Pub Date : 2023-06-27 DOI: 10.53941/ijddp.2023.100002
Haishan Xu, J. Duan, J. Tao, Wen Wang, Yunqing Wu, S. Dai, Jun Ren
Article Oxidized LDL Regulates Endothelin-1 and Oxidative Stress in Vascular Endothelial Cells: Role of Extracellular Regulated Kinase1/2 (ERK1/2) Haishan Xu 1,#, Jinhong Duan 1,#, Jun Tao 2, Wen Wang 3, Yunqing Wu 1,^, Shunling Dai 1,*, and Jun Ren 4,5, 1 Faculty of Basic Medicine, Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing 100005 China 2 Department of Cardiovascular Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510000 China 3 Department of Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China 4 Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032, China 5 National Clinical Research Center for Interventional Medicine, Shanghai 200032, China # These two authors contributed equally to this work ^ Deceased * Correspondence: daishunling@aliyun.com (Shunling Dai); corresponding author:jren_aldh2@outlook.com (Jun Ren)     Abstract: It is perceived that oxidized low density lipoprotein (oxLDL) perturbs endothelial function and fosters endothelin-1 (ET-1) secretion although the underlying mechanism remains elusive. This study was designed to decipher potential mechanisms underscoring oxLDL-evoked regulation of ET-1 and signaling pathways involved in endothelial cells. ET-1 mRNA expression, secretion and promoter function were determined using RT-PCR, enzyme immunometric and luciferase assays, respectively. GO and GSEA bioinformatics analyses depicted differentially expressed genes (DEGs) mainly associated with cell proliferation, cell division, cellular structure, energy supply, and apoptosis in oxLDL-challenged endothelial cells. Incubation of oxLDL overtly increased ROS production, apoptosis, mRNA level, secretion and promoter activity of ET-1 in human umbilical vein endothelial cells (HUVECs), the effects were mitigated by N-Acetyl Cysteine (NAC). Moreover, oxLDL challenge evoked phosphorylation of extracellular signal-regulated kinase1/2 (ERK1/2) in HUVECs, the effect was reversed by NAC and MEK inhibitor PD98059. NAC and PD98059 nullified oxLDL- induced rises in mRNA expression, secretion and promoter activity of ET-1. Truncation of 5’-flanking sequence of ET-1 (–566 bpLuc to –250 bpLuc) displayed elevated luciferase activity with 24-h oxLDL incubation. Fusion plasmid from –233 and –185 bp Luc drastically dampened luciferase activity in basal and oxLDL-challenged HUVECs. Transfection of reporter construct –250 bp Luc with a 2 bp mutation at AP-1 locus, removed basal and oxLDL- evoked rises in ET-1 promoter activity. Collectively, our findings support that oxLDL evoked activation of ERK1/2 signaling likely through ROS production, en route to upregulation of endothelial transcriptional factor AP-1, resulting in expression and secretion of ET-1.
氧化LDL调节血管内皮细胞内皮素-1和氧化应激细胞外调节Kinase1/2 (ERK1/2)的作用徐海山1,#,段金红1,#,陶军2,王文3,吴云青1,^,戴顺玲1,*,任军4,5,1北京协和医学院基础医学院,中国医学科学院基础医学研究所,北京100005 2中山大学孙逸仙纪念医院心血管外科,广州510000 3基础医学院病理生理科,广州510000首都医科大学心内科,北京100069 4复旦大学中山医院心内科,上海200032 5国家介入医学临床研究中心,上海200032 #两位作者对本文贡献相同^已逝世*通信:daishunling@aliyun.com(戴顺玲);摘要:氧化低密度脂蛋白(oxLDL)可干扰内皮功能,促进内皮素-1 (ET-1)分泌,但其机制尚不明确。本研究旨在揭示氧化低密度脂蛋白诱发的内皮细胞中ET-1调控和信号通路的潜在机制。分别采用RT-PCR、酶免疫测定和荧光素酶测定测定ET-1 mRNA的表达、分泌和启动子功能。GO和GSEA生物信息学分析描述了差异表达基因(DEGs)主要与氧化低密度脂蛋白应激内皮细胞的细胞增殖、细胞分裂、细胞结构、能量供应和凋亡相关。oxLDL明显增加人脐静脉内皮细胞(HUVECs) ROS的产生、凋亡、mRNA水平、ET-1的分泌和启动子活性,n -乙酰半胱氨酸(NAC)可减轻这种影响。此外,oxLDL攻击引起HUVECs细胞外信号调节激酶1/2 (ERK1/2)的磷酸化,NAC和MEK抑制剂PD98059逆转了这一作用。NAC和PD98059消除了oxLDL诱导的ET-1 mRNA表达、分泌和启动子活性的升高。截断ET-1的5 ' -侧翼序列(-566 bpLuc至-250 bpLuc),在oxLDL孵育24小时后显示荧光素酶活性升高。来自-233 bp和-185 bp Luc的融合质粒极大地抑制了基础和氧化ldl挑战的huvec中荧光素酶的活性。在AP-1位点转染报告基因- 250 bp的Luc和2 bp的突变,消除了基础和oxLDL引起的ET-1启动子活性升高。总的来说,我们的研究结果支持oxLDL可能通过ROS的产生激活ERK1/2信号,在内皮转录因子AP-1上调的过程中,导致ET-1的表达和分泌。
{"title":"Oxidized LDL Regulates Endothelin-1 and Oxidative Stress in Vascular Endothelial Cells: Role of Extracellular Regulated Kinase1/2 (ERK1/2)","authors":"Haishan Xu, J. Duan, J. Tao, Wen Wang, Yunqing Wu, S. Dai, Jun Ren","doi":"10.53941/ijddp.2023.100002","DOIUrl":"https://doi.org/10.53941/ijddp.2023.100002","url":null,"abstract":"Article Oxidized LDL Regulates Endothelin-1 and Oxidative Stress in Vascular Endothelial Cells: Role of Extracellular Regulated Kinase1/2 (ERK1/2) Haishan Xu 1,#, Jinhong Duan 1,#, Jun Tao 2, Wen Wang 3, Yunqing Wu 1,^, Shunling Dai 1,*, and Jun Ren 4,5, 1 Faculty of Basic Medicine, Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing 100005 China 2 Department of Cardiovascular Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510000 China 3 Department of Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China 4 Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032, China 5 National Clinical Research Center for Interventional Medicine, Shanghai 200032, China # These two authors contributed equally to this work ^ Deceased * Correspondence: daishunling@aliyun.com (Shunling Dai); corresponding author:jren_aldh2@outlook.com (Jun Ren)     Abstract: It is perceived that oxidized low density lipoprotein (oxLDL) perturbs endothelial function and fosters endothelin-1 (ET-1) secretion although the underlying mechanism remains elusive. This study was designed to decipher potential mechanisms underscoring oxLDL-evoked regulation of ET-1 and signaling pathways involved in endothelial cells. ET-1 mRNA expression, secretion and promoter function were determined using RT-PCR, enzyme immunometric and luciferase assays, respectively. GO and GSEA bioinformatics analyses depicted differentially expressed genes (DEGs) mainly associated with cell proliferation, cell division, cellular structure, energy supply, and apoptosis in oxLDL-challenged endothelial cells. Incubation of oxLDL overtly increased ROS production, apoptosis, mRNA level, secretion and promoter activity of ET-1 in human umbilical vein endothelial cells (HUVECs), the effects were mitigated by N-Acetyl Cysteine (NAC). Moreover, oxLDL challenge evoked phosphorylation of extracellular signal-regulated kinase1/2 (ERK1/2) in HUVECs, the effect was reversed by NAC and MEK inhibitor PD98059. NAC and PD98059 nullified oxLDL- induced rises in mRNA expression, secretion and promoter activity of ET-1. Truncation of 5’-flanking sequence of ET-1 (–566 bpLuc to –250 bpLuc) displayed elevated luciferase activity with 24-h oxLDL incubation. Fusion plasmid from –233 and –185 bp Luc drastically dampened luciferase activity in basal and oxLDL-challenged HUVECs. Transfection of reporter construct –250 bp Luc with a 2 bp mutation at AP-1 locus, removed basal and oxLDL- evoked rises in ET-1 promoter activity. Collectively, our findings support that oxLDL evoked activation of ERK1/2 signaling likely through ROS production, en route to upregulation of endothelial transcriptional factor AP-1, resulting in expression and secretion of ET-1.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81139244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Small Leucine Rich Proteoglycan in Fibrotic Diseases: New Frenemies? 富含亮氨酸的小蛋白多糖在纤维化疾病中的作用:新的友敌?
Pub Date : 2023-06-27 DOI: 10.53941/ijddp.2023.100005
Jiayu Guo, Yan Wang, Haihai Liang, Baofeng Yang
ReviewSmall Leucine Rich Proteoglycan in Fibrotic Diseases: New Frenemies?Jiayu Guo 1,2, Yan Wang 1,2, Haihai Liang 1,2,3,*, and Baofeng Yang 1,2,3,*1 Department of Pharmacology (National Key Laboratory of Frigid Zone Cardiovascular Diseases), College of Pharmacy, Harbin Medical University, Harbin 150081, China2 Northern Translational Medicine Research and Cooperation Center, Heilongjiang Academy of Medical Sciences, Harbin Medical University, Harbin 150081, China3 Research Unit of Noninfectious Chronic Diseases in Frigid Zone (2019RU070), Chinese Academy of Medical Sciences, Harbin 150081, China* Correspondence: lianghaihai@ems.hrbmu.edu.cn (H.H.L),; yangbf@ems.hrbmu.edu.cn (B.F.Y)  Received: 27 April 2023Accepted: 2 June 2023 Abstract: The human body is a complex organism with self-regulating ability and can cope with external pressures and challenges. To protect the body from damage during exercise or confrontations, beneath the human epidermal layer, the human body has evolved a coverall gown: the extracellular matrix (ECM). ECM provides a suitable space for the survival and activity of cells in the body, and affects the behavior of cells through signal transduction system. Proteoglycans, particularly the small leucine rich proteoglycan (SLRP) family, have been shown to be molecules that play important roles in matrix remodeling and organ fibrosis, such as by affecting ECM components or altering the intracellular environment. But in recent years reports of SLRP families, their manifestations in different organs have not been consistent. Recent studies suggest that proteoglycans entering the blood in a soluble form hold promise as diagnostic biomarkers of organ fibrosis and may provide novel therapeutic strategies for fibrotic diseases. Herein, we discuss and review studies of SLRPs in multi-organ fibrotic diseases.
富含亮氨酸的小蛋白多糖在纤维化疾病中的作用:新的友敌?郭佳玉1,2,王燕1,2,梁海海1,2,3,*,杨宝峰1,2,3,*1哈尔滨医科大学药学院药学系(寒带心血管疾病国家重点实验室),哈尔滨150081;哈尔滨医科大学黑龙江医学科学院北方转化医学研究合作中心,哈尔滨150081;中国医学科学院,哈尔滨150081 *通讯:lianghaihai@ems.hrbmu.edu.cn (H.H.L),;yangbf@ems.hrbmu.edu.cn (B.F.Y)收稿日期:2023年4月27日收稿日期:2023年6月2日摘要:人体是一个具有自我调节能力的复杂生物体,能够应对外界的压力和挑战。为了保护身体在运动或对抗中免受伤害,在人体表皮层之下,人体进化出了一种全身外衣:细胞外基质(ECM)。ECM为细胞在体内的生存和活动提供了适宜的空间,并通过信号转导系统影响细胞的行为。蛋白聚糖,特别是小亮氨酸富蛋白聚糖(SLRP)家族,已被证明是在基质重塑和器官纤维化中发挥重要作用的分子,例如通过影响ECM成分或改变细胞内环境。但近年来关于SLRP家族的报道,其在不同器官的表现并不一致。最近的研究表明,以可溶性形式进入血液的蛋白多糖有望作为器官纤维化的诊断生物标志物,并可能为纤维化疾病提供新的治疗策略。在此,我们讨论和回顾slrp在多器官纤维化疾病中的研究。
{"title":"Small Leucine Rich Proteoglycan in Fibrotic Diseases: New Frenemies?","authors":"Jiayu Guo, Yan Wang, Haihai Liang, Baofeng Yang","doi":"10.53941/ijddp.2023.100005","DOIUrl":"https://doi.org/10.53941/ijddp.2023.100005","url":null,"abstract":"Review\u0000Small Leucine Rich Proteoglycan in Fibrotic Diseases: New Frenemies?\u0000\u0000Jiayu Guo 1,2, Yan Wang 1,2, Haihai Liang 1,2,3,*, and Baofeng Yang 1,2,3,*\u0000\u0000\u00001 Department of Pharmacology (National Key Laboratory of Frigid Zone Cardiovascular Diseases), College of Pharmacy, Harbin Medical University, Harbin 150081, China\u00002 Northern Translational Medicine Research and Cooperation Center, Heilongjiang Academy of Medical Sciences, Harbin Medical University, Harbin 150081, China\u00003 Research Unit of Noninfectious Chronic Diseases in Frigid Zone (2019RU070), Chinese Academy of Medical Sciences, Harbin 150081, China\u0000* Correspondence: lianghaihai@ems.hrbmu.edu.cn (H.H.L),; yangbf@ems.hrbmu.edu.cn (B.F.Y)\u0000 \u0000 \u0000Received: 27 April 2023\u0000Accepted: 2 June 2023\u0000 \u0000\u0000Abstract: The human body is a complex organism with self-regulating ability and can cope with external pressures and challenges. To protect the body from damage during exercise or confrontations, beneath the human epidermal layer, the human body has evolved a coverall gown: the extracellular matrix (ECM). ECM provides a suitable space for the survival and activity of cells in the body, and affects the behavior of cells through signal transduction system. Proteoglycans, particularly the small leucine rich proteoglycan (SLRP) family, have been shown to be molecules that play important roles in matrix remodeling and organ fibrosis, such as by affecting ECM components or altering the intracellular environment. But in recent years reports of SLRP families, their manifestations in different organs have not been consistent. Recent studies suggest that proteoglycans entering the blood in a soluble form hold promise as diagnostic biomarkers of organ fibrosis and may provide novel therapeutic strategies for fibrotic diseases. Herein, we discuss and review studies of SLRPs in multi-organ fibrotic diseases.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"73 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88511823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Advances in Natural Plant-based Treatment of Myocardial Ischemia-reperfusion Injury 天然植物治疗心肌缺血再灌注损伤的研究进展
Pub Date : 2023-06-27 DOI: 10.53941/ijddp.2023.100003
Peixun Yang, Minxuan Liu, Xiaoxue Fan, Xinzhuang Zhang, Liang Cao, Zhenzhong Wang, W. Xiao
ReviewRecent Advances in Natural Plant-based Treatment of Myocardial Ischemia-reperfusion InjuryPeixun Yang 1,3,4, Minxuan Liu 2,3,4, Xiaoxue Fan 3,4, Xinzhuang Zhang 3,4, Liang Cao 3,4, Zhenzhong Wang 3,4, and Wei Xiao 3,4, *1 Kanion School of Chinese Materia Medica, Nanjing University of Chinese Medicine, 138 Xianlin Avenue Qixia District, Nanjing 210046, China2 School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Avenue Qixia District, Nanjing 210046, China3 National Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Jiangning Industrial City, Economic and Technological Development Zone of Lianyungang, Lianyungang 222001, China4 Jiangsu Kanion Pharmaceutical Co Ltd, Jiangning Industrial City, Economic and Technological Development Zone of Lianyungang, Lianyungang 222001, China* Correspondence: xw_kanion@163.com ( Wei Xiao)  Received: 23 March 2023Accepted: 10 May 2023 Abstract: Cardiovascular disease (CDV) is the primary cause of death in the world, and myocardial ischemia (MI) is one of the high-risk CVDs. The myocardial blood supply must be restored as soon as possible to reduce the mortality risk, however, reperfusion itself paradoxically leads to further death of cardiomyocytes and increases the infarct size; this is known as myocardial ischemia/reperfusion injury (MIRI). The pathological mechanism of MIRI is complex, and current research mainly focuses on oxidative stress, dysfunctional mitochondrial energy metabolism, Ca 2+ overload, endoplasmic reticulum stress (ERs) and the inflammatory response. This review briefly summarizes the mechanism of MIRI, and natural plant product (NPP) components proven to ameliorate MIRI and their related signaling pathways. NPPs can alleviate MIRI by regulating oxidative stress, inflammation, ERs, Ca 2+ overload and mitochondrial function maintenance. This review will deepen our understanding of how NPPs reduce MIRI and the future value of NPPs in cardio-protection.
天然植物治疗心肌缺血再灌注损伤的研究进展[杨培勋1,3,4,刘敏轩2,3,4,樊晓雪3,4,张新庄3,4,曹亮3,4,王振忠3,4,肖伟3,4]*1南京中医药大学康宁中药学院,南京栖霞区仙林大道138号,210046;2南京中医药大学药学院,南京栖霞区仙林大道138号,210046;3连云港经济技术开发区江宁工业城,连云港222001;4连云港经济技术开发区江宁工业城,江苏康宁药业有限公司,连云港222001 *通讯:xw_kanion@163.com(魏晓)摘要:心血管疾病(CDV)是全球死亡的首要原因,心肌缺血(MI)是高危心血管疾病之一。心肌血供必须尽快恢复,以降低死亡风险,然而,再灌注本身矛盾地导致心肌细胞进一步死亡并增加梗死面积;这被称为心肌缺血/再灌注损伤(MIRI)。MIRI的病理机制复杂,目前的研究主要集中在氧化应激、线粒体能量代谢功能障碍、ca2 +超载、内质网应激(endoplasmic reticulum stress, ERs)和炎症反应等方面。本文就MIRI的作用机制、已证实改善MIRI的天然植物产物(natural plant product, NPP)成分及其相关信号通路作一综述。核电厂可通过调节氧化应激、炎症、内质网、ca2 +超载和线粒体功能维持来缓解MIRI。这篇综述将加深我们对NPPs如何降低MIRI以及NPPs在心脏保护中的未来价值的理解。
{"title":"Recent Advances in Natural Plant-based Treatment of Myocardial Ischemia-reperfusion Injury","authors":"Peixun Yang, Minxuan Liu, Xiaoxue Fan, Xinzhuang Zhang, Liang Cao, Zhenzhong Wang, W. Xiao","doi":"10.53941/ijddp.2023.100003","DOIUrl":"https://doi.org/10.53941/ijddp.2023.100003","url":null,"abstract":"Review\u0000Recent Advances in Natural Plant-based Treatment of Myocardial Ischemia-reperfusion Injury\u0000\u0000Peixun Yang 1,3,4, Minxuan Liu 2,3,4, Xiaoxue Fan 3,4, Xinzhuang Zhang 3,4, Liang Cao 3,4, Zhenzhong Wang 3,4, and Wei Xiao 3,4, *\u0000\u0000\u00001 Kanion School of Chinese Materia Medica, Nanjing University of Chinese Medicine, 138 Xianlin Avenue Qixia District, Nanjing 210046, China\u00002 School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Avenue Qixia District, Nanjing 210046, China\u00003 National Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Jiangning Industrial City, Economic and Technological Development Zone of Lianyungang, Lianyungang 222001, China\u00004 Jiangsu Kanion Pharmaceutical Co Ltd, Jiangning Industrial City, Economic and Technological Development Zone of Lianyungang, Lianyungang 222001, China\u0000* Correspondence: xw_kanion@163.com ( Wei Xiao)\u0000 \u0000 \u0000Received: 23 March 2023\u0000Accepted: 10 May 2023\u0000 \u0000\u0000Abstract: Cardiovascular disease (CDV) is the primary cause of death in the world, and myocardial ischemia (MI) is one of the high-risk CVDs. The myocardial blood supply must be restored as soon as possible to reduce the mortality risk, however, reperfusion itself paradoxically leads to further death of cardiomyocytes and increases the infarct size; this is known as myocardial ischemia/reperfusion injury (MIRI). The pathological mechanism of MIRI is complex, and current research mainly focuses on oxidative stress, dysfunctional mitochondrial energy metabolism, Ca 2+ overload, endoplasmic reticulum stress (ERs) and the inflammatory response. This review briefly summarizes the mechanism of MIRI, and natural plant product (NPP) components proven to ameliorate MIRI and their related signaling pathways. NPPs can alleviate MIRI by regulating oxidative stress, inflammation, ERs, Ca 2+ overload and mitochondrial function maintenance. This review will deepen our understanding of how NPPs reduce MIRI and the future value of NPPs in cardio-protection.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87771300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathophysiological Mechanisms and Pharmaceutical Interventions of Myocardial Infarction with Depression 心肌梗死伴抑郁的病理生理机制及药物干预
Pub Date : 2023-06-27 DOI: 10.53941/ijddp.2023.100004
Mingyang Xu, Yinxiang Wei, Zhenhui Wang, Yaohui Wang, Xiaoming Zhong, Qiying Chen
ReviewPathophysiological Mechanisms and Pharmaceutical Interventions of Myocardial Infarction with DepressionMingyang Xu 1, Yinxiang Wei 2, Zhenhui Wang 1, Yaohui Wang 2, Xiaoming Zhong 3,*, and Qiying Chen 4,*1 School of medicine, Henan University, Kaifeng 475000, China.2 Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng 475004, China.3 Department of Cardiology, Huaihe Hospital of Henan University, Kaifeng 475000, China.4 Department of Cardiology, Huashan Hospital, Fudan University, Shanghai 200040, China.* Correspondence: Xiaoming Zhong (zxm10020202@126.com); Qiying Chen (chenqiying@huashan.org.cn)  Received: 23 March 2023Accepted: 10 May 2023 Abstract: The strong association between acute myocardial infarction (AMI) and major depression disorder(MDD)is a universally accepted. Patients with AMI complicated by MDD often have poor prognosis. Most early studies focused on how AMI leads to MDD, but there are few reports on depression-induced AMI. In terms of mechanism, inflammation, the hypothalamic-pituitary-adrenal axis (HPA axis) and brain-gut axis may be involved in the occurrence and development of MDD after AMI. The inflammatory injury, abnormal sympathetic and vagal nerve activity, HPA axis overactivation, overeating and some therapeutic medicine administration in patients with MDD can also be risk factors for AMI. Both behavioral and pharmaceutical interventions are important for the treatment of AMI with MDD. More drugs are being developed and tested. At present, there are still many issues, needing to be addressed, in the diagnosis, pathogenesis, intervention strategies and therapeutic drugs for AMI with MDD. To aid clinical diagnosis and treatment, this review classifies the existing studies on AMI complicated with MDD, and also includes some of our considerations.
徐明阳1,魏银祥2,王振辉1,王耀辉2,钟晓明3,*,陈启英4,*1河南大学医学院,开封475000 2河南大学抗体药物工程国家联合实验室,开封475004 3河南大学淮河医院心内科,开封475000 4心内科,开封475000复旦大学附属华山医院,上海200040*通讯:钟晓明(zxm10020202@126.com);摘要:急性心肌梗死(AMI)与重度抑郁障碍(MDD)之间的密切关联已被普遍接受。AMI合并重度抑郁症的患者往往预后较差。大多数早期的研究都集中在AMI如何导致重度抑郁症上,但关于抑郁症引起的AMI的报道很少。从机制上看,炎症、下丘脑-垂体-肾上腺轴(HPA轴)和脑肠轴可能参与AMI后MDD的发生发展。MDD患者的炎症损伤、交感和迷走神经活动异常、HPA轴过度激活、暴饮暴食和一些治疗性药物的使用也可能是AMI的危险因素。行为和药物干预对AMI合并重度抑郁症的治疗都很重要。更多的药物正在开发和测试中。目前,AMI合并MDD的诊断、发病机制、干预策略和治疗药物等方面仍有许多问题需要解决。为了帮助临床诊断和治疗,本文对AMI合并MDD的现有研究进行了分类,并包括了我们的一些考虑。
{"title":"Pathophysiological Mechanisms and Pharmaceutical Interventions of Myocardial Infarction with Depression","authors":"Mingyang Xu, Yinxiang Wei, Zhenhui Wang, Yaohui Wang, Xiaoming Zhong, Qiying Chen","doi":"10.53941/ijddp.2023.100004","DOIUrl":"https://doi.org/10.53941/ijddp.2023.100004","url":null,"abstract":"Review\u0000Pathophysiological Mechanisms and Pharmaceutical Interventions of Myocardial Infarction with Depression\u0000\u0000Mingyang Xu 1, Yinxiang Wei 2, Zhenhui Wang 1, Yaohui Wang 2, Xiaoming Zhong 3,*, and Qiying Chen 4,*\u0000\u0000\u00001 School of medicine, Henan University, Kaifeng 475000, China.\u00002 Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng 475004, China.\u00003 Department of Cardiology, Huaihe Hospital of Henan University, Kaifeng 475000, China.\u00004 Department of Cardiology, Huashan Hospital, Fudan University, Shanghai 200040, China.\u0000* Correspondence: Xiaoming Zhong (zxm10020202@126.com); Qiying Chen (chenqiying@huashan.org.cn)\u0000 \u0000 \u0000Received: 23 March 2023\u0000Accepted: 10 May 2023\u0000 \u0000\u0000Abstract: The strong association between acute myocardial infarction (AMI) and major depression disorder(MDD)is a universally accepted. Patients with AMI complicated by MDD often have poor prognosis. Most early studies focused on how AMI leads to MDD, but there are few reports on depression-induced AMI. In terms of mechanism, inflammation, the hypothalamic-pituitary-adrenal axis (HPA axis) and brain-gut axis may be involved in the occurrence and development of MDD after AMI. The inflammatory injury, abnormal sympathetic and vagal nerve activity, HPA axis overactivation, overeating and some therapeutic medicine administration in patients with MDD can also be risk factors for AMI. Both behavioral and pharmaceutical interventions are important for the treatment of AMI with MDD. More drugs are being developed and tested. At present, there are still many issues, needing to be addressed, in the diagnosis, pathogenesis, intervention strategies and therapeutic drugs for AMI with MDD. To aid clinical diagnosis and treatment, this review classifies the existing studies on AMI complicated with MDD, and also includes some of our considerations.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"89 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85964398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanism of Anti-seizure Medications and Emerging Trends in Epilepsy Treatment 抗癫痫药物的作用机制及癫痫治疗的新趋势
Pub Date : 2023-06-27 DOI: 10.53941/ijddp.2023.100001
Z. S. Rana, Reena Suman, Shobi Veleri, Pradeep Punnakkal
ReviewMechanism of Anti-seizure Medications and Emerging Trends in Epilepsy TreatmentZubin Singh Rana 1, Reena Suman 1, Shobi Veleri 2, and Pradeep Punnakkal 1, *1 Department of Biophysics, Postgraduate Institute of Medical Education and Research Chandigarh, 160012, India2 Drug Safety Division, ICMR-National Institute of Nutrition, Hyderabad, 500007, India.* Correspondence: p.pradeep@pgimer.edu.in  Received: 28 November 2022Accepted: 24 January 2023 Abstract: About one percent of the world’s population is affected by epilepsy. Epilepsy-induced psychiatric co-morbidity and mortality impose a huge burden on patients, their families, and society. Anti-seizure medications (ASMs) are drugs used to control seizures in patients with epilepsy. Epilepsy constitutes a spectrum of disorders, with various underlying causes. Hence, finding the right drug to control seizures with minimal side effects is a difficult task for clinicians. Besides controlling seizures, many ASMs have off-target effects that result in unwanted side effects. Compared to first and second-generation drugs, third-generation drugs have shown better tolerance. Even though the target of many ASMs is known, their mechanism of action is not well understood. The main mechanism behind epilepsy is defined as an imbalance in the excitatory-to-inhibitory ratio in neurotransmission. So, the key target of ASMs is the ion channels controlling the intrinsic property of neurons like sodium channels, potassium channels, and calcium channels, the excitatory synaptic transmission via glutamate receptors, and the inhibitory synaptic transmission by GABA receptors. Here we review the role of ion channels in epilepsy, and how the ASMs act on them for seizure control.
抗癫痫药物的作用机制和癫痫治疗的新趋势zubin Singh Rana 1, Reena Suman 1, Shobi Veleri 2, Pradeep Punnakkal 1, *1印度医学教育与研究研究生院生物物理学系,昌迪加尔,160012 2印度国际医学研究委员会-国家营养研究所药物安全部,海得拉巴,500007*通讯:p.pradeep@pgimer.edu.in收稿日期:2022年11月28日接受日期:2023年1月24日摘要:世界上约有1%的人口受到癫痫的影响。癫痫引起的精神疾病的合并症和死亡率给病人、他们的家庭和社会带来了巨大的负担。抗癫痫药物(asm)是用于控制癫痫患者癫痫发作的药物。癫痫是一系列疾病,有各种潜在病因。因此,找到合适的药物来控制癫痫发作和最小的副作用对临床医生来说是一项艰巨的任务。除了控制癫痫发作外,许多抗痉挛药物还会产生意想不到的副作用。与第一代和第二代药物相比,第三代药物的耐受性更好。尽管许多asm的靶点是已知的,但它们的作用机制尚不清楚。癫痫背后的主要机制被定义为神经传递中兴奋性与抑制性比例的不平衡。因此,asm的主要作用靶点是控制神经元固有特性的钠通道、钾通道、钙通道等离子通道,以及谷氨酸受体的兴奋性突触传递和GABA受体的抑制性突触传递。在这里,我们回顾离子通道在癫痫中的作用,以及asm如何作用于它们以控制癫痫发作。
{"title":"Mechanism of Anti-seizure Medications and Emerging Trends in Epilepsy Treatment","authors":"Z. S. Rana, Reena Suman, Shobi Veleri, Pradeep Punnakkal","doi":"10.53941/ijddp.2023.100001","DOIUrl":"https://doi.org/10.53941/ijddp.2023.100001","url":null,"abstract":"Review\u0000Mechanism of Anti-seizure Medications and Emerging Trends in Epilepsy Treatment\u0000\u0000Zubin Singh Rana 1, Reena Suman 1, Shobi Veleri 2, and Pradeep Punnakkal 1, *\u0000\u0000\u00001 Department of Biophysics, Postgraduate Institute of Medical Education and Research Chandigarh, 160012, India\u00002 Drug Safety Division, ICMR-National Institute of Nutrition, Hyderabad, 500007, India.\u0000* Correspondence: p.pradeep@pgimer.edu.in\u0000 \u0000 \u0000Received: 28 November 2022\u0000Accepted: 24 January 2023\u0000 \u0000\u0000Abstract: About one percent of the world’s population is affected by epilepsy. Epilepsy-induced psychiatric co-morbidity and mortality impose a huge burden on patients, their families, and society. Anti-seizure medications (ASMs) are drugs used to control seizures in patients with epilepsy. Epilepsy constitutes a spectrum of disorders, with various underlying causes. Hence, finding the right drug to control seizures with minimal side effects is a difficult task for clinicians. Besides controlling seizures, many ASMs have off-target effects that result in unwanted side effects. Compared to first and second-generation drugs, third-generation drugs have shown better tolerance. Even though the target of many ASMs is known, their mechanism of action is not well understood. The main mechanism behind epilepsy is defined as an imbalance in the excitatory-to-inhibitory ratio in neurotransmission. So, the key target of ASMs is the ion channels controlling the intrinsic property of neurons like sodium channels, potassium channels, and calcium channels, the excitatory synaptic transmission via glutamate receptors, and the inhibitory synaptic transmission by GABA receptors. Here we review the role of ion channels in epilepsy, and how the ASMs act on them for seizure control.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"86 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73923511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is miR-21 A Therapeutic Target in Cardiovascular Disease? miR-21是心血管疾病的治疗靶点吗?
Pub Date : 2023-04-01 Epub Date: 2023-01-11 DOI: 10.53941/ijddp.0201003
Antoinette Holland, Molly Enrick, Arianna Diaz, Liya Yin

microRNA-21 (miR-21) serves a multitude of functions at the molecular level through its regulation of messenger RNA. Previous research has sparked interest in the role of miR-21 as a potential therapeutic target in cardiovascular diseases. miR-21 expression contributes to the differentiation, proliferation, and maturation of many cell types, such as fibroblasts, endothelial cells, cardiomyocytes, and endothelial progenitor cells. The function of miR-21 depends upon its expression level in the specific cell types and downstream targets, which determine cell fate. Under pathological conditions, the expression level of miR-21 is altered, leading to abnormal gene regulation of downstream signaling and cardiovascular diseases such as hypertension, cardiac hypertrophy and fibrosis, atherosclerosis, and heart failure. Agomirs or antagomirs can be introduced into the respective tissue type to reverse or stop the progression of the disease. Exosomes in the extracellular vesicles, which mediate many cellular events with high biocompatibility, have a high potential of efficiently delivering miR-21 to their targeted cells. The critical role of miR-21 in cardiovascular disease (CVD) is indisputable, but there are controversial reports on the function of miR-21 in the same disease. This discrepancy sparks interest in better understanding the role of miR-21 in different tissues under different stages of various diseases and the mechanism of how miR-21 inhibitors work.

微小RNA-21(miR-21)通过调节信使RNA在分子水平上发挥多种功能。先前的研究激发了人们对miR-21作为心血管疾病潜在治疗靶点的作用的兴趣。miR-21的表达有助于许多细胞类型的分化、增殖和成熟,如成纤维细胞、内皮细胞、心肌细胞和内皮祖细胞。miR-21的功能取决于其在特定细胞类型和下游靶点中的表达水平,这些靶点决定了细胞的命运。在病理条件下,miR-21的表达水平发生改变,导致下游信号传导和心血管疾病的异常基因调节,如高血压、心肌肥大和纤维化、动脉粥样硬化和心力衰竭。可以将激动剂或抗酸剂引入相应的组织类型中,以逆转或阻止疾病的进展。细胞外囊泡中的外泌体以高生物相容性介导许多细胞事件,具有将miR-21有效递送到靶细胞的高潜力。miR-21在心血管疾病(CVD)中的关键作用是无可争议的,但关于miR-21在同一疾病中的功能,有争议的报道。这种差异激发了人们对更好地理解miR-21在各种疾病不同阶段的不同组织中的作用以及miR-21抑制剂如何发挥作用的兴趣。
{"title":"Is miR-21 A Therapeutic Target in Cardiovascular Disease?","authors":"Antoinette Holland,&nbsp;Molly Enrick,&nbsp;Arianna Diaz,&nbsp;Liya Yin","doi":"10.53941/ijddp.0201003","DOIUrl":"10.53941/ijddp.0201003","url":null,"abstract":"<p><p>microRNA-21 (miR-21) serves a multitude of functions at the molecular level through its regulation of messenger RNA. Previous research has sparked interest in the role of miR-21 as a potential therapeutic target in cardiovascular diseases. miR-21 expression contributes to the differentiation, proliferation, and maturation of many cell types, such as fibroblasts, endothelial cells, cardiomyocytes, and endothelial progenitor cells. The function of miR-21 depends upon its expression level in the specific cell types and downstream targets, which determine cell fate. Under pathological conditions, the expression level of miR-21 is altered, leading to abnormal gene regulation of downstream signaling and cardiovascular diseases such as hypertension, cardiac hypertrophy and fibrosis, atherosclerosis, and heart failure. Agomirs or antagomirs can be introduced into the respective tissue type to reverse or stop the progression of the disease. Exosomes in the extracellular vesicles, which mediate many cellular events with high biocompatibility, have a high potential of efficiently delivering miR-21 to their targeted cells. The critical role of miR-21 in cardiovascular disease (CVD) is indisputable, but there are controversial reports on the function of miR-21 in the same disease. This discrepancy sparks interest in better understanding the role of miR-21 in different tissues under different stages of various diseases and the mechanism of how miR-21 inhibitors work.</p>","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"2 1","pages":"26-36"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41169497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
New Tale of Metformin in Cardio-Oncology 二甲双胍在心脏肿瘤学中的新进展
Pub Date : 2023-04-01 DOI: 10.53941/ijddp.0201001
X. Wang
EditorialNew Tale of Metformin in Cardio-OncologyXin Wang ,Faculty of Biology, Medicine and Health, University of Manchester, Oxford Road, M139PT Manchester, UK.* Correspondence: xin.wang@manchester.ac.uk
编辑:二甲双胍在心脏肿瘤中的新故事王欣,曼彻斯特大学生物、医学与健康学院,曼彻斯特牛津路M139PT*通信:xin.wang@manchester.ac.uk
{"title":"New Tale of Metformin in Cardio-Oncology","authors":"X. Wang","doi":"10.53941/ijddp.0201001","DOIUrl":"https://doi.org/10.53941/ijddp.0201001","url":null,"abstract":"Editorial\u0000New Tale of Metformin in Cardio-Oncology\u0000\u0000Xin Wang ,\u0000\u0000\u0000Faculty of Biology, Medicine and Health, University of Manchester, Oxford Road, M139PT Manchester, UK.\u0000* Correspondence: xin.wang@manchester.ac.uk\u0000","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73491682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Minimally Invasive Approach for Cardiac Electrophysiology Studies in Mice 一种用于小鼠心脏电生理研究的微创方法
Pub Date : 2023-03-25 DOI: 10.53941/ijddp.0201006
M. Zi, S. Abraham, A. D’Souza, D. Hutchings, S. Prehar, Xin Wang, E. Cartwright
ReviewA Minimally Invasive Approach for Cardiac Electrophysiology Studies in MiceMin Zi , * , Sabu Abraham , Alicia D'souza , David Hutchings , Sukhpal Prehar , Xin Wang , and Elizabeth J CartwrightDivision of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, United Kingdom* Correspondence: min.zi@manchester.ac.uk  Received: 6 January 2023Accepted: 9 February 2023Published: 25 March 2023 Abstract: Atrial fibrillation and ventricular tachycardia are commonly seen in clinic. Different approaches have been developed to investigate underlying mechanisms. Transvenous approach (TA) is widely used for studies but has several drawbacks. We therefore developed a novel minimally invasive approach (MIA) for mechanistic studies. Study included 27 male C57BL/6J mice, 19 for MIA and 8 for TA. Under general anaesthesia, ECG was recorded. A key hole was made on the right first intercostal space by separating the intercostal muscles, followed by the exposure of the superior vena cava and the top of the atrium. An EPR-800 catheter was inserted vertically, perpendicular to the chest, for atrial pacing and flatly over the ventricles for ventricular pacing. Burst S1–S1 and decremental S1–S2 pacing protocols were performed to evaluate SA recovery time (SNRT), the atrioventricular node effective refractory period (AVN-ERP), Wenckebach period, ventricular ERP, and arrhythmia susceptibility. MIA was successfully performed in all 19 mice without any complications. One mouse died during TA due to venous rupture. Compared MIA with TA, surgical time were significantly shorter (P<0.0001). Wenckebach period was shorter as well (P<0.05). No difference was found in baseline sinus cycle length, SNRT, correct SNRT, AVN-ERP, ventricular ERP, and arrhythmia susceptibility (all P>0.05). The novel MIA outplays TA by providing similar outcomes of PES but consuming less time, demanding less surgical expertise, and reducing the potential of surgical complications. Given the minimal tissue injury, it also provides great potential as a recovery procedure for longitudinal study.
emin Zi, *, Sabu Abraham, Alicia D'souza, David Hutchings, Sukhpal Prehar, Xin Wang, Elizabeth J cartwright,英国曼彻斯特大学生物医学与健康学院心血管科学分科,曼彻斯特M13 9PL *通讯:min.zi@manchester.ac.uk收稿:2023年1月6日接受:2023年2月9日发表:摘要:房颤和室性心动过速是临床上常见的两种疾病。已经开发了不同的方法来研究潜在的机制。经静脉入路(TA)广泛用于研究,但有几个缺点。因此,我们开发了一种新的微创入路(MIA)用于机制研究。研究对象为27只雄性C57BL/6J小鼠,其中MIA 19只,TA 8只。在全身麻醉下,记录心电图。通过分离肋间肌,在右侧第一肋间隙开一个关键孔,然后暴露上腔静脉和心房顶部。垂直插入EPR-800导管,垂直于胸部,用于心房起搏,平放于心室上方,用于心室起搏。采用Burst S1-S1和递减S1-S2起搏方案评估SA恢复时间(SNRT)、房室结有效不应期(AVN-ERP)、Wenckebach期、心室ERP和心律失常易感性。19只小鼠均成功行MIA,无并发症。1只小鼠因静脉破裂死亡。相比于MIA和TA,手术时间明显缩短(P0.05)。新型MIA优于TA,因为它提供了与PES相似的结果,但花费的时间更短,需要的手术专业知识更少,并且减少了手术并发症的可能性。考虑到最小的组织损伤,它也为纵向研究提供了巨大的潜力。
{"title":"A Minimally Invasive Approach for Cardiac Electrophysiology Studies in Mice","authors":"M. Zi, S. Abraham, A. D’Souza, D. Hutchings, S. Prehar, Xin Wang, E. Cartwright","doi":"10.53941/ijddp.0201006","DOIUrl":"https://doi.org/10.53941/ijddp.0201006","url":null,"abstract":"Review\u0000A Minimally Invasive Approach for Cardiac Electrophysiology Studies in Mice\u0000\u0000Min Zi , * , Sabu Abraham , Alicia D'souza , David Hutchings , Sukhpal Prehar , Xin Wang , and Elizabeth J Cartwright\u0000\u0000\u0000Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, United Kingdom\u0000* Correspondence: min.zi@manchester.ac.uk\u0000 \u0000 \u0000Received: 6 January 2023\u0000Accepted: 9 February 2023\u0000Published: 25 March 2023\u0000 \u0000\u0000Abstract: Atrial fibrillation and ventricular tachycardia are commonly seen in clinic. Different approaches have been developed to investigate underlying mechanisms. Transvenous approach (TA) is widely used for studies but has several drawbacks. We therefore developed a novel minimally invasive approach (MIA) for mechanistic studies. Study included 27 male C57BL/6J mice, 19 for MIA and 8 for TA. Under general anaesthesia, ECG was recorded. A key hole was made on the right first intercostal space by separating the intercostal muscles, followed by the exposure of the superior vena cava and the top of the atrium. An EPR-800 catheter was inserted vertically, perpendicular to the chest, for atrial pacing and flatly over the ventricles for ventricular pacing. Burst S1–S1 and decremental S1–S2 pacing protocols were performed to evaluate SA recovery time (SNRT), the atrioventricular node effective refractory period (AVN-ERP), Wenckebach period, ventricular ERP, and arrhythmia susceptibility. MIA was successfully performed in all 19 mice without any complications. One mouse died during TA due to venous rupture. Compared MIA with TA, surgical time were significantly shorter (P<0.0001). Wenckebach period was shorter as well (P<0.05). No difference was found in baseline sinus cycle length, SNRT, correct SNRT, AVN-ERP, ventricular ERP, and arrhythmia susceptibility (all P>0.05). The novel MIA outplays TA by providing similar outcomes of PES but consuming less time, demanding less surgical expertise, and reducing the potential of surgical complications. Given the minimal tissue injury, it also provides great potential as a recovery procedure for longitudinal study.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"133 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87208815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Promising Treatments for Duchenne Muscular Dystrophy: Restoring Dystrophin Protein Expression Using Nucleic Acid Therapeutics 有希望的治疗杜氏肌营养不良:利用核酸疗法恢复营养不良蛋白的表达
Pub Date : 2023-02-11 DOI: 10.53941/ijddp.0201002
G. Hu, Chen Chen
ReviewPromising Treatments for Duchenne Muscular Dystrophy: Restoring Dystrophin Protein Expression Using Nucleic Acid TherapeuticsGuo Hu  and Chen Chen *Division of Cardiology and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.* Correspondence: chenchen@tjh.tjmu.edu.cn; Tel. & Fax: 86-27-6937-8422  Received: 10 October 2022Accepted: 4 November 2022Published: 11 January 2023 Abstract: Duchenne muscular dystrophy is caused by inadequate generation of functional dystrophin protein. Traditional clinical treatments can only slightly mitigate the progression of the disease, but not completely stem or reverse the decline in muscle function. Therapies aimed at dystrophin recovery are currently under development, among which are exon skipping and stop codon readthrough therapies. They are now used in clinics, while gene addition therapies are in phase III clinical trials. Gene editing therapies have also been approved for the first clinical trial recently. This review will discuss these emerging therapies, clinical trials, and directions for future developments.
*华中科技大学同济医学院同济医院心脏科,心脏科遗传与分子机制湖北省重点实验室,武汉。*通信:chenchen@tjh.tjmu.edu.cn;收稿日期:2022年10月10日收稿日期:2022年11月4日发表日期:2023年1月11日摘要:杜氏肌营养不良症是由功能性肌营养不良蛋白产生不足引起的。传统的临床治疗只能轻微缓解疾病的进展,但不能完全阻止或逆转肌肉功能的下降。针对肌营养不良蛋白恢复的治疗方法目前正在开发中,其中包括外显子跳跃和停止密码子读取疗法。它们现在用于临床,而基因添加疗法处于III期临床试验。基因编辑疗法最近也首次被批准进行临床试验。本文将讨论这些新兴疗法、临床试验和未来发展方向。
{"title":"Promising Treatments for Duchenne Muscular Dystrophy: Restoring Dystrophin Protein Expression Using Nucleic Acid Therapeutics","authors":"G. Hu, Chen Chen","doi":"10.53941/ijddp.0201002","DOIUrl":"https://doi.org/10.53941/ijddp.0201002","url":null,"abstract":"Review\u0000Promising Treatments for Duchenne Muscular Dystrophy: Restoring Dystrophin Protein Expression Using Nucleic Acid Therapeutics\u0000\u0000Guo Hu  and Chen Chen *\u0000\u0000\u0000Division of Cardiology and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.\u0000* Correspondence: chenchen@tjh.tjmu.edu.cn; Tel. & Fax: 86-27-6937-8422\u0000 \u0000 \u0000Received: 10 October 2022\u0000Accepted: 4 November 2022\u0000Published: 11 January 2023\u0000 \u0000\u0000Abstract: Duchenne muscular dystrophy is caused by inadequate generation of functional dystrophin protein. Traditional clinical treatments can only slightly mitigate the progression of the disease, but not completely stem or reverse the decline in muscle function. Therapies aimed at dystrophin recovery are currently under development, among which are exon skipping and stop codon readthrough therapies. They are now used in clinics, while gene addition therapies are in phase III clinical trials. Gene editing therapies have also been approved for the first clinical trial recently. This review will discuss these emerging therapies, clinical trials, and directions for future developments.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80762766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biological Functions and Applications of Exosomes in Drug Research 外泌体的生物学功能及其在药物研究中的应用
Pub Date : 2023-02-11 DOI: 10.53941/ijddp.0201008
Mengmeng Fu, Jiapeng Li, Tungalag Battulga, Xiaoxue Li, Ming Xu
ReviewBiological Functions and Applications of Exosomes in Drug ResearchMengmeng Fu 1, Jiapeng Li 1, Tungalag Battulga 2, Xiaoxue Li 3, *, and Ming Xu 1, *1 Department of Clinical Pharmacy, School of Preclinical Medicine and Clinical Pharmacy, China Pharmaceutical University, 24 Tong jia Lane, Nanjing 210009, China.2 School of Pharmacy, Mongolian National University of Medical Sciences, Ulaanbaatar-24210, Mongolia.3 Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.* Correspondence: lxx84112@163.com(Xiaoxue Li); mingxu@cpu.edu.cn; Tel.: 025-86185653(Ming Xu)  Received: 9 October 2022Accepted: 12 November 2022Published: 11 January 2023 Abstract: Exosomes have received increasing attention in recent years as an important substance for intercellular communication. Among the plethora of new research is their unique interaction with drugs is even more striking. Exosomes play essential roles in disease treatment either as extracellular vesicles to exert biological functions or as drug carriers to deliver therapeutic agents. We summarized the relationship between exosomes and drugs in the disease progression and treatment. Understanding how exosomes interact with drugs and exert their anti-inflammatory and pro-angiogenic effects, alongside a lipid peroxidation inhibitory result in different manners is essential for disease treatment.
外泌体的生物学功能及其在药物研究中的应用综述傅梦梦1,李佳鹏1,Tungalag Battulga 2,李晓雪3,*,徐明1,*1中国药科大学基础医学与临床药学院临床药学系,南京同家弄24号210009 .2蒙古医科大学药学院,蒙古乌兰巴托24210 .3蒙古医科大学中大医院心内科东南大学,江苏南京210009*通信:lxx84112@163.com(李晓雪);mingxu@cpu.edu.cn;摘要:外泌体作为细胞间通讯的重要物质,近年来受到越来越多的关注。在大量的新研究中,它们与药物的独特相互作用更加引人注目。外泌体作为细胞外囊泡发挥生物学功能或作为药物载体递送治疗剂在疾病治疗中发挥重要作用。我们总结了外泌体与药物在疾病进展和治疗中的关系。了解外泌体如何与药物相互作用并发挥其抗炎和促血管生成作用,以及以不同方式抑制脂质过氧化的结果,对疾病治疗至关重要。
{"title":"Biological Functions and Applications of Exosomes in Drug Research","authors":"Mengmeng Fu, Jiapeng Li, Tungalag Battulga, Xiaoxue Li, Ming Xu","doi":"10.53941/ijddp.0201008","DOIUrl":"https://doi.org/10.53941/ijddp.0201008","url":null,"abstract":"Review\u0000Biological Functions and Applications of Exosomes in Drug Research\u0000\u0000Mengmeng Fu 1, Jiapeng Li 1, Tungalag Battulga 2, Xiaoxue Li 3, *, and Ming Xu 1, *\u0000\u0000\u00001 Department of Clinical Pharmacy, School of Preclinical Medicine and Clinical Pharmacy, China Pharmaceutical University, 24 Tong jia Lane, Nanjing 210009, China.\u00002 School of Pharmacy, Mongolian National University of Medical Sciences, Ulaanbaatar-24210, Mongolia.\u00003 Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.\u0000* Correspondence: lxx84112@163.com(Xiaoxue Li); mingxu@cpu.edu.cn; Tel.: 025-86185653(Ming Xu)\u0000 \u0000 \u0000Received: 9 October 2022\u0000Accepted: 12 November 2022\u0000Published: 11 January 2023\u0000 \u0000\u0000Abstract: Exosomes have received increasing attention in recent years as an important substance for intercellular communication. Among the plethora of new research is their unique interaction with drugs is even more striking. Exosomes play essential roles in disease treatment either as extracellular vesicles to exert biological functions or as drug carriers to deliver therapeutic agents. We summarized the relationship between exosomes and drugs in the disease progression and treatment. Understanding how exosomes interact with drugs and exert their anti-inflammatory and pro-angiogenic effects, alongside a lipid peroxidation inhibitory result in different manners is essential for disease treatment.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78032966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International journal of drug discovery and pharmacology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1